In agreement with a previous, and far more exhaustive analysis of human tumor genomic data [33], we find that the majority of the human lung adenocarcinomas analyzed had a mutation spectrum favoring a subset of mutations that included the known oncogenic KRAS mutation of the tumor. This evidence concerns the gene KRAS and lung adenocarcinoma.